scholarly journals ABO GENE AND AGING-RELATED OUTCOMES IN OVER 379,000 EUROPEAN-DESCENT PARTICIPANTS OF UK BIOBANK

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S925-S925
Author(s):  
Chia-Ling Kuo ◽  
Ziwei Pan ◽  
Luke C Pilling ◽  
George A Kuchel ◽  
David Melzer
Keyword(s):  
Breast Cancer ◽  
Type Ii Diabetes ◽  
Hemoglobin Concentration ◽  
Blood Type ◽  
Type Ii ◽  
Nucleotide Polymorphisms ◽  
Multiple Traits ◽  
Mineral Density ◽  
Blood Types ◽  
Wide Range

Abstract Genetic variants associated with multiple traits are potential targets to delay aging. Drugs supported by genetic evidence are twice as likely to succeed in human trials. Single nucleotide polymorphisms (SNPs) in the ABO gene were reported by genome-wide associations studies, associated with breast cancer, coronary artery disease, stroke, and type II diabetes. To evaluate the potential of ABO gene as a target for aging intervention, we conducted a phenome-wide association study (PheWAS) to associate the genotype-derived blood types (based on two SNPs in the ABO gene) with a wide range of aging-related outcomes. The genotype-derived blood type distribution (41% A, 9% B, 3% AB, and 47% O) is similar to that reported by the UK National Health Service (39% A, 10% B, 3% AB, and 48% O). The blood type was not associated with parental lifespan or extreme parental longevity. Non-O types had modestly lower risk of hypertension than O type but higher risk of type II diabetes and pancreatic cancer (e.g., OR= 1.37, 95% CI: 1.17 to 1.59 comparing A to O). Additionally, “A" type had modestly higher risk of breast cancer than other types. “A” allele (in A or AB type) was associated with lower heel bone mineral density, alkaline phosphatase (e.g., 0.41 standard deviation lower in A than that in O, 95% CI: -0.42 to -0.40), and hemoglobin concentration, but higher HbA1c, direct LDL, and cholesterol. Blood types with A allele(s) are less favored than other blood types, which however are adversely associated with some aging traits.

scholarly journals Outcome of breast cancer patients regarding obesity and complications: Analysis of risk factors

2021 ◽  
Vol 68 (1) ◽  
pp. 77-86
Author(s):  
Iuliana Pantelimon ◽  
◽  
Laurentia Nicoleta Gales ◽  
Maria Daniela Tanasescu ◽  
Irina Nita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Prognostic Factors ◽  
Disease Progression ◽  
Body Mass ◽  
Type Ii Diabetes ◽  
The Body ◽  
Proliferation Index ◽  
Her2 Overexpression ◽  
Type Ii

Introduction. Breast cancer is the leading cause of cancer death in Romania. In the context in which the treatments available for this pathology have increased curability, the identification of negative prognostic factors involved in the evolution of this disease seems essential to improve the overall survival as well as the time to disease progression. Aim. The aim of this study is to identify the role of prognostic factors such as ki67 proliferation index, the presence of tumour estrogen receptors, HER2 overexpression, the presence of secondary determinations at diagnosis, the association of obesity and type II diabetes. Methods. 50 patients diagnosed with breast cancer treated in the Elias University Emergency Hospital Bucharest were retrospectively followed, for which the progression was documented at the time of elaboration of this study. Thus, a database was developed in which data were entered on age, body mass index, immunohistochemical characteristics of breast tumours, the presence/absence of metastases at diagnosis and the association of type II diabetes. Statistical calculations were performed to highlight a possible correlation between obesity (quantified by measuring body mass index) and tumour aggressiveness (quantified by ki67 proliferation index) as well as statistical evaluation of potential prognostic factors that would influence time, until the disease progresses. Results. Within this group, no correlation could be established between the presence of an increased body mass index and the value of the ki67 proliferation index (p = 0.38). The mean value of the body mass index for this group of unselected patients was 28.76 ± 4.81 (DS) most patients are therefore overweight or obese. The factors involved in the evolution of breast cancer that influenced the early progression of the disease were: the proliferation index ki67 (p <0.05), the presence of metastases at diagnosis (p < 0.0001) and the association of type II diabetes (p = 0.0085). The value of the body mass index did not influence the time to disease progression according to statistical calculations in this group probably due to the small number of normal weight patients included (p = 0.34).

scholarly journals Cancer Biology and Prevention in Diabetes

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1380 ◽  
Author(s):  
Swayam Prakash Srivastava ◽  
Julie E. Goodwin
Keyword(s):  
Type Ii Diabetes ◽  
Cancer Biology ◽  
Cancer Metastasis ◽  
Type I Diabetes ◽  
Type I ◽  
Type Ii ◽  
Mesenchymal Transition ◽  
Wide Range ◽  
Risk Of Cancer

The available evidence suggests a complex relationship between diabetes and cancer. Epidemiological data suggest a positive correlation, however, in certain types of cancer, a more complex picture emerges, such as in some site-specific cancers being specific to type I diabetes but not to type II diabetes. Reports share common and differential mechanisms which affect the relationship between diabetes and cancer. We discuss the use of antidiabetic drugs in a wide range of cancer therapy and cancer therapeutics in the development of hyperglycemia, especially antineoplastic drugs which often induce hyperglycemia by targeting insulin/IGF-1 signaling. Similarly, dipeptidyl peptidase 4 (DPP-4), a well-known target in type II diabetes mellitus, has differential effects on cancer types. Past studies suggest a protective role of DPP-4 inhibitors, but recent studies show that DPP-4 inhibition induces cancer metastasis. Moreover, molecular pathological mechanisms of cancer in diabetes are currently largely unclear. The cancer-causing mechanisms in diabetes have been shown to be complex, including excessive ROS-formation, destruction of essential biomolecules, chronic inflammation, and impaired healing phenomena, collectively leading to carcinogenesis in diabetic conditions. Diabetes-associated epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndMT) contribute to cancer-associated fibroblast (CAF) formation in tumors, allowing the epithelium and endothelium to enable tumor cell extravasation. In this review, we discuss the risk of cancer associated with anti-diabetic therapies, including DPP-4 inhibitors and SGLT2 inhibitors, and the role of catechol-o-methyltransferase (COMT), AMPK, and cell-specific glucocorticoid receptors in cancer biology. We explore possible mechanistic links between diabetes and cancer biology and discuss new therapeutic approaches.

scholarly journals Ketogenic Diet: Golden Intervention for Breast Cancer Patients with Type II Diabetes Mellitus an Intervention Study, Mansoura, Egypt

2021 ◽  
Vol 12 (1) ◽  
pp. 1435-1446
Author(s):  
Aml Ahmed Mohammed ELmetwaly ◽  
Entisar Gaad El moula Shaaban ◽  
Ateya Megahed Ibrahim ◽  
Safaa Salem Salem Shetawy ◽  
Eman Mahmoud Hafez Mohamed
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Cancer Patients ◽  
Ketogenic Diet ◽  
Type Ii Diabetes ◽  
Intervention Study ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Breast Cancer Patients

Type II diabetes and breast cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 1552-1552
Author(s):  
K. D. Erickson ◽  
J. P. Pierce ◽  
R. E. Patterson ◽  
T. R. Reid ◽  
L. Natarajan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Type Ii Diabetes ◽  
Type Ii

ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1572-1572
Author(s):  
Yuksel Urun ◽  
Tulay Koru-Sengul ◽  
Kadri Altundag ◽  
Gungor Utkan ◽  
Handan Onur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Blood Group ◽  
Blood Groups ◽  
Blood Type ◽  
Abo Blood Group ◽  
Abo Blood Groups ◽  
Blood Types ◽  
Abo Blood Type

1572 Background: The role of genetic factors in the development of cancer is widely accepted. ABO blood type is an inherited characteristic and previous studies have observed an association between ABO blood group and risk of certain malignancies, including pancreatic and gastric cancer. The data on the role of ABO blood group and Rh factor in breast cancer is inconclusive. Methods: All patients who had breast cancer (BC) and treated between 2000-2010 at the Departments of Medical Oncology of both Ankara and Hacettepe Universities (Ankara, Turkey) with defined ABO blood type and Rh factor were included in our retrospective reviews of tumor registry records. A group of volunteer healthy women donors of Turkish Red Crescent between 2004-2011 were identified as a control group, without any matching factors. The relationship of ABO blood types and Rh factor with various prognostic factors such as age at diagnosis, menopausal status, family history of breast cancer, and ER/PR/HER2 status were evaluated from 1740 BC patients. We compared the distributions of ABO blood types, Rh factors among 1740 patients and 204,553 healthy controls. Among BC patients, differences between each of aforementioned ABO blood groups and Rh factors with respect to various prognostic factors were explored, respectively. Results: Overall distributions of ABO blood groups as well as Rh factor were comparable between patients (44% A, 8% AB, 16% B, 32% O, 88% Rh+) and controls (41% A, 8% AB, 16% B, 35% O, 87% Rh+). However, there were statistically significant differences between patients and controls with respect to A vs. nonA (p=0.019) and marginal significance (p=0.051) for O vs. nonO. Among patients, there were statistically significant differences between A and nonA with respect to HER2 (p=0.0421), M stage (p=0.0447), T stage (p=0.0020). Only T stage (p=0.0337) were significantly different between O vs nonO. Grade (p=0.0227) and M stage (p=0.0107) were significantly different between Rh factors. Conclusions: In our study sample, ABO blood type was statistically significantly associated with breast cancer. Additional studies are necessary to determine the mechanisms by which ABO blood type may influence the risk of breast cancer.

A Review on Analytical Methods for Estimation of Linagliptin in Bulk and Tablet Dosage form

2021 ◽  
pp. 127-132
Author(s):  
Premjit S Nannaware ◽  
Suhas S. Siddheshwar ◽  
M.H. Kolhe
Keyword(s):  
Analytical Methods ◽  
Type Ii Diabetes ◽  
Analytical Techniques ◽  
Cost Effective ◽  
Pharmaceutical Formulations ◽  
Accurate Method ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Dipeptidyl Peptidase 4 ◽  
Wide Range

Linagliptin is an oral anti- diabetic drug that reduces blood sugar (glucose) levels in patients with type 2 diabetes. Linagliptin is a member of a class of drugs that inhibit the enzyme, dipeptidyl peptidase-4 (DPP-4 inhibitors). It is widely used in the treatment of type –II diabetes mellitus which is characterized by insulin resistance in peripheral tissue and insulin secretory defect of the β – cells. Linagliptin is been approved by the US food and Drug administration 2 may 2011 for the management of type –II diabetes. There are a wide range of analytical techniques were available for the analysis of linagliptin in pharmaceutical and biological samples. HPLC with UV detection is applicable in the case of analysis of linagliptin in pharmaceuticals which provide us cost effective accurate method when compare with more advance techniques. This review depicts the reported Spectrophotometric and Chromatographic methods; developed and validated for estimation of Linagliptin alone or on combination with Metformin or Empagliflozin. This review focus on different analytical methods for the estimation of Linagliptin in pharmaceutical formulations. From this elaborate literature review it was found that, till date there is no RP-HPLC method available for the determination of Linagliptin with Metformin or Empagliflozine using Design of Expert or Quality by Design.

GLYCOSYLATED HEMOGLOBIN IN THE DIAGNOSIS AND CONTROL OF TYPE II DIABETES MELLITUS

Vestnik ◽  
2021 ◽  
pp. 173-178
Author(s):  
М.А. Дуйсекова ◽  
Д. Алимова ◽  
А.С. Айткулова ◽  
А. Райымжанкызы ◽  
Д.Б. Ногайбай ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type Ii Diabetes ◽  
Glycosylated Hemoglobin ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Wide Range ◽  
Impaired Insulin ◽  
Hypoglycemic Therapy ◽  
And Control

Сахарный диабет характеризуется нарушением секреции инсулина и той или иной степенью инсулинорезистентности, обусловливающими гипергликемию. Диабет в 2 раза повышает риски появления широкого спектра сердечно-сосудистых заболеваний, в 6 раз повышает риски ИБС. ХБП развивается примерно у 35% пациентов с сахарным диабетом II типа и ассоциирован с повышенной смертностью. В Казахстане исследования на эту тему проведены не были. Уровень гликозилированного гемоглобина отражает состояние компенсации углеводного обмена, показывает эффективность сахароснижающей терапии и определяет стратегию лечения пациента. Diabetes mellitus is characterized by impaired insulin secretion and varying degrees of insulin resistance, causing hyperglycemia. Diabetes increases the risk of a wide range of cardiovascular diseases by 2 times, and increases the risk of CHD by 6 times. CKD develops in approximately 35% of patients with type II diabetes and is associated with increased mortality. No studies on this topic have been conducted in Kazakhstan. The level of glycosylated hemoglobin reflects the state of carbohydrate metabolism compensation, shows the effectiveness of hypoglycemic therapy and determines the patient's treatment strategy.

Bone mineral density in women with type II diabetes mellitus

2009 ◽  
Vol 4 (1) ◽  
pp. 97-101 ◽  
Author(s):  
Ruth S. Weinstock ◽  
Robin S. Goland ◽  
Elizabeth Shane ◽  
Thomas L. Clemens ◽  
Robert Lindsay ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document